Replies to post #96336 on $heff's $tation of $tocks & $olid DD

[beach_trades]

$MRUS at 19 now we getting 6 pps (25%) off what $INCY paid for investment. Wedbush has target now at 32
http://www.bizjournals.com/philadelphia/news/2016/12/21/incyte-merus-netherlands-antibody-bispecific-tech.html?ana=yahoo

and presenting at ASCO. will report the full dataset from the Phase 1 study of HER2 × HER3 MCLA-128 http://247wallst.com/healthcare-business/2017/05/27/top-presentations-to-look-for-at-asco/

http://phoenix.corporate-ir.net/phoenix.zhtml?c=254206&p=irol-newsArticle_print&ID=2263434

The company said it will initiate the Phase 2 clinical trial in the second half of 2017, exploring two metastatic breast cancer populations, namely HER2-positive patients and hormone receptor-positive/HER2-low patients. https://www.benzinga.com/general/biotech/17/05/9488518/the-most-notable-abstracts-released-ahead-of-asco-2017